Apixaban Eliquis For Preventing Venous Thromboembolism After Knee Or Hip Replacement Surgery. Apixaban does not require antithrombin iii for antithrombotic activity, and it has no direct effect on platelet aggregation.19 On march 13, 2014, the fda approved apixaban for the prophylaxis of dvt, which may lead to pe, in patients who have undergone hip or knee replacement surgery.16,17 on august 21, 2014, apixaban received supplemental approval for the treatment of dvt and pe, and for risk reduction of recurrent dvt and pe after initial therapy.18,19 apixaban was first approved by the fda on december 28, 2012, to reduce the risk for stroke and systemic embolism in patients with nonvalvular atrial fibrillation (nvaf).19,20 this approval was contingent on the manufacturer’s provision of a risk evaluation and mitigation strategies program to inform healthcare professionals about the increased risk for thrombotic events, including stroke, when apixaban is prematurely discontinuing without an adequate alternative anticoagulant use.19 the fda approved apixaban for dvt prophylaxis and for the prevention of pe, in patients.
Apixaban offers a safe, effective, and convenient oral alternative for patients undergoing total hip replacement surgery or total knee replacement surgery, patients who require treatment for vte, and patients in whom prophylaxis is needed to reduce the risk for recurrent vte after initial therapy.
Apixaban is contraindicated in patients with active pathologic bleeding and in patients who have had severe hypersensitivity reactions, including anaphylaxis, to apixaban.19 John tan, 20 years in vein care Indwelling epidural or intrathecal catheters should not be removed until 24 hours after the last apixaban dose, and the next apixaban dose should be administered at least 5 hours after cathet. Because treatment is likely to increase the risk for hemorrhage during pregnancy and delivery, apixaban should be used during pregnancy only if the potential benefit outweighs the potential risk for the mother and the fetus.19 labor and delivery the safety and efficacy of apixaban during labor and delivery have not been studied in clinical trials.
Post a Comment for "Apixaban Eliquis For Preventing Venous Thromboembolism After Knee Or Hip Replacement Surgery"